TY - JOUR ID - 18475 TI - Clinical usefulness of Somatostatin Receptor Scintigraphy in the Diagnosis of Neuroendocrine Neoplasms JO - Asia Oceania Journal of Nuclear Medicine and Biology JA - AOJNMB LA - en SN - 2322-5718 AU - Inaba, Yoshitaka AU - Hijioka, Susumu AU - Iwama, Isanori AU - Asai, Tsubasa AU - Miyamura, Hiroki AU - Chatani, Shohei AU - Hasegawa, Takaaki AU - Murata, Schinichi AU - Kato, Mina AU - Sato, Yozo AU - Yamaura, Hidekazu AU - Onaya, Hiroaki AU - Shimizu, Junichi AU - Hara, Kazuo AD - Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan AD - Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan Y1 - 2022 PY - 2022 VL - 10 IS - 1 SP - 1 EP - 13 KW - neuroendocrine neoplasms (NEN) KW - Neuroendocrine Tumor (NET) KW - somatostatin receptor scintigraphy (SRS) KW - Indium-111 pentetreotide Octreo scan DO - 10.22038/aojnmb.2021.56254.1390 N2 - Objective(s): We investigated the detectability of somatostatin receptor scintigraphy (SRS) for neuroendocrine neoplasms (NEN). Methods: From January 2016 to October 2020, 125 SRS examinations using indium-111 pentetreotide performed for patients with NEN lesions were retrospectively evaluated. The detection rate of NEN lesions was determined according to histopathological classification by primary site and by organ. Results: At least one NEN lesion was detected in 73% (91/125) with a positive Krenning score of ≥2 in SRS. The detection of abdominal NENs (gastrointestinal tract, 38; pancreas, 62; and others, 14) was 89% (49/55) for neuroendocrine tumor (NET)-grade (G) 1, 78% (32/41) for NET-G2, 66% (2/3) for NET-G3, 31% (4/13) for neuroendocrine carcinoma (NEC), 100% (1/1) for mixed neuroendocrine–non-neuroendocrine neoplasm, and 0% (0/1) for non-classified NEN. That of thoracic NENs was 33% (2/6) for typical carcinoid tumor and 40% (2/5) for atypical carcinoid tumor. For a total of 226 organ lesions, hepatic lesions were 76% (58/76); pancreatic lesions, 61% (31/51); lymph node lesions, 77% (27/35); bone lesions, 83% (20/24); duodenal lesions, 82% (9/11); and other lesions, 41% (11/27). Conclusion: The detectability of SRS for NEN in Japan was verified at a center, and its usefulness was confirmed.  UR - https://aojnmb.mums.ac.ir/article_18475.html L1 - https://aojnmb.mums.ac.ir/article_18475_c5e177d4d75b6b024164a6b49a7d907c.pdf ER -